Overview

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.
Phase:
Phase 3
Details
Lead Sponsor:
Ironshore Pharmaceuticals and Development, Inc
Treatments:
Methylphenidate